FT : Bad smell lingers around Royal Mail share sale

Bad smell lingers around Royal Mail share sale

Sir, The news that Lazard Asset Management made a profit of £8m for its clients, by selling shares in the privatisation of Royal Mail during the first week of trading, is not in itself a surprise.

The real surprise for those outside the City should be that investment banks are still permitted to own asset management businesses, which can invest on behalf of others in the deals that their investment banking colleagues advise on.
After all, Chinese walls are there to be breached, knowingly or otherwise.
Moreover, if Chinese walls have to be put in place to try to avoid conflicts of interest, then perhaps the businesses should be owned and managed separately as wholly independent and autonomous entities, to remove the possibility of such conflicts altogether.
The additional fact that 12 of the 16 “priority” investors reneged
on their “gentlemen’s agreement” with the UK government, by selling off their shares almost immediately and generating massive short-term profits, adds to the whiff of cosy impropriety by City insiders.
So, while this episode might have been entirely legal and above board, however credibly those concerned may protest their innocence, if the man on the street thinks it smells bad, then it probably does

>>> Siemens held lengthy board debate on bid for Alstom power division

Siemens held lengthy board debate on bid for Alstom power division

Siemens, the German technology company, does not have unanimous internal support for its bid for Alstom's power division, hence it held a very long board meeting on the matter, Frankfurter Allgemeine reported.

Citing unidentified sources at Siemens, the German-language daily said that debates over the EUR 11bn offer for French rival Alstom's power operations meant that the board meeting lasted five hours, before ultimately approving the bid.

The daily was told that some at Siemens consider the deal risky and expensive, and fear the overlaps of the businesses are too big and the need for restructuring too considerable. In the event of the takeover going ahead, according to the sources, Siemens might spend years integrating the operations.

The report also noted that Juergen Wechsler of the German trade union IG Metall has asked for assurances of roughly 11,500 jobs remaining at Siemens' transport technology operations in the event of a takeover.


Source Frankfurter Allgemeine Zeitung

>>> Asian Update

Asian Market Update: Australia homes sales growth slows, wholesale inflation accelerates due to softer AUD

***Economic Data*** - (AU) AUSTRALIA Q1 PPI Q/Q: 0.9% V 0.6%E; Y/Y: 2.5% V 2.2%E - (AU) AUSTRALIA MAR HIA NEW HOME SALES M/M: 0.2% (3-month low) V 4.6% PRIOR - (JP) JAPAN APR MONETARY BASE Y/Y: 48.5% V 54.8% PRIOR - (JP) JAPAN MAR OVERALL HOUSEHOLD SPENDING Y/Y: +7.2% V +2.0%E (multi-year high) - (JP) JAPAN MAR JOBLESS RATE: 3.6% (matches 6-year low) V 3.6%E; JOB-TO-APPLICANT RATIO: 1.07 V 1.06E - (NZ) NEW ZEALAND APR ANZ COMMODITY PRICE M/M: -4.0% (biggest decline in 2 years) V -0.1% PRIOR - (KR) SOUTH KOREA APR HSBC MANUFACTURING PMI: 50.2 V 50.4 PRIOR - (TW) TAIWAN APR HSBC MANUFACTURING PMI: 52.3 V 52.7 PRIOR (weakest PMI since Sept 2013) - (VN) VIETNAM APR HSBC MANUFACTURING PMI: 53.1 (record high; 8 months of expansion) V 51.3 PRIOR - (ID) INDONESIA APR CPI M/M: 0.0% V 0.1%E; Y/Y: 7.3% V 7.3%E; CORE CPI: 4.7% V 4.7%E - (ID) INDONESIA MAR EXPORTS Y/Y: +1.2% V -1.1%E - (ID) INDONESIA APR HSBC MANUFACTURING PMI: 51.1 V 50.1 PRIOR

Market Snapshot (as of 03:30 GMT): - Nikkei225 -0.2%, S&P/ASX +0.1%, Kospi -0.2%, Shanghai Composite closed, Hang Seng +0.6%, Jun S&P500 +0.1% at 1,878, Jun gold +0.1% at $1,284, Jun crude oil +0.1% at $99.47/brl

***Highlights/Observations/Insights*** - Australia is in the spotlight in terms of economic data for today's session that was otherwise marked by its typically low pre-NFP (non farm payrolls) volatility. HIA new home sales rose for the 3rd consecutive month but also at the lowest pace in 3 months. Australia's Q1 PPI - reported over a week after the lower than expected CPI - was surprisingly higher, but a closer look suggested the weaker AUD was responsible for much of the PPI gains. According to Australia Stats Bureau, price rise reflected an increase of 0.7% in the prices of domestically produced products and a increase of 2.7% for imported products. ASB said "the depreciation of the Australian dollar against major trading currencies contributed to this rise."

- On the corporate front, Australia's Myer Holdings reported a 0.9% decline in Q3 revenues while LFL sales rose 0.2%. Macquarie Group posted slightly better than expected FY14 net profit and 330bp rise in ROE, however tier 1 ratio declined 10bps and loan impairment rose moderately. Shares of MYR fell over 2% and MQG was up slightly.

- China Index Academy reported the average price of new residential properties across 100 major cities rising for the 23rd consecutive month but very marginally - April's 0.1% growth slowed from 0.4%. The academy noted the "growth in home prices, both monthly and annually, has narrowed for the fourth straight month in April, with the number of cities registering price increases falling notably... A couple of factors, including policy loosening in some cities and continuing tighter credit at commercial banks, further boosted a wait-and-see sentiment among some home seekers." Shanghai Composite remains closed for holiday until Monday.

- Japan's Sony opened sharply lower after cutting its projections for the FY13/14 after close on Thursday. Unemployment rate in Japan remained steady in March at its 6-year low of 3.6%, prompting Chief Cabinet Sec Suga to remark that labor situation is steadily improving. Separately, local press indicated Japan govt will consider a corporate tax cut from FY15/16, in line with recent remarks from cabinet officials.

- Entering the 2nd half of the Asian session, financial press reports surfaced of a "large-scale" attack by Ukraine military on the center of pro-Russian rebels stronghold town of Slaviansk. Gold and Yen pairs remained little changed on the reports.

***Fixed Income/Commodities/Currencies*** - (JP) BOJ offers to buy ¥110B in JGB with maturity below 1-yr, ¥400B in 5-10 yr JGB as well as ¥2.5T T-bills - (AU) Australia MoF (AOFM) sells A$700M in 5.25% 2019 Bonds; avg yield: 3.2795%; bid-to-cover: 5.08x - (JP) Japan investors bought net ¥70.8B in foreign bonds last week vs sold net ¥418.2B in prior week; Foreign Investors bought net ¥195.9B in Japan stocks v bought net ¥194.0B in prior week - GLD: SPDR Gold Trust ETF daily holdings fall 2.3 tonnes to 785.6 tonnes (lowest since Jan 2009) - (US) Weekly Fed Balance Sheet Total Assets Week ending April 30th: $4.30T v $4.30T prior; Reserve Bank Credit: $4.25T v $4.25T prior; M1: +$4.9B v +$28.3B prior; M2: -$25.8B v +$25.2B prior; M1 y/y change: 10.4% (6-month high) v 10.2% w/w; M2 y/y change: 6.1% v 6.1% w/w

***Equities*** US markets: - NTRI: Reports Q1 $0.01 v -$0.03e, R$122.2M v $121Me; +14.8% afterhours - SKUL: Reports Q1 -$0.12 v -$0.17e, R$39.1M v $39.2Me; +9.0% afterhours - AEM: Reports Q1 $0.61 adj v $0.25e, R$491.8M v $445Me; +5.3% afterhours - MCRS: Reports Q3 $0.72 v $0.66e, R$349M v $333Me; +4.1% afterhours - QLGC: Reports Q4 $0.24 v $0.22e, R$115.7M v $114Me; +3.4% afterhours - WYNN: Reports Q1 $2.32 v $2.11e, R$1.51B v $1.48Be; +2.5% afterhours - OUTR: Reports Q1 $1.27(adj) v $0.92e, R$600.4M v $585Me; +2.1% afterhours - AKAM: Reports Q1 $0.58 v $0.53e, R$454M v $440Me; Guides Q2 $0.53-0.57 v $0.53e, R$464-478M v $458Me - conf call; +1.5% afterhours - VRTX: Reports Q1 -$0.65 v -$0.70e, R$118M v $137Me; +1.4% afterhours - WU: Reports Q1 $0.37 v $0.35e, R$1.35B v $1.35Be; +1.0% afterhours - KRFT: Reports Q1 $0.85 v $0.78e, R$4.36B v $4.50Be; -0.7% afterhours - EXPE: Reports Q1 $0.16 v $0.13e, R$1.20B v $1.18Be; -2.5% afterhours - FLR: Reports Q1 $0.92 v $0.96e, R$5.38B v $6.55Be (unclear if comparable); -3.4% afterhours - LNKD: Reports Q1 $0.38 v $0.35e, R$473.2M v $468Me; Raises FY14 guidance; -4.4% afterhours - MTW: Reports Q1 $0.17 v $0.22e, R$850M v $920Me; -5.1% afterhours - OPEN: Reports Q1 $0.45 adj v $0.42e, R$53.8M v $54.4Me; -6.7% afterhours

Notable movers by sector: - Consumer Discretionary: Wynn Macau 1128.HK +4.4% (Q1 results); Myer Holdings MYR.AU -2.3% (Q3 results) - Financials: Macquarie Group Limited MQG.AU +1.0% (FY14 results) - Industrials: China Railway Group 390.HK +9.3%, China Railway Construction Corp 1186.HK +7.2% (China Vice Premier comments on railway) - Technology: Sony Corp 6758.JP -1.5% (guides FY13/14) - Utilities: Oki Electric Industry 6703.JP +3.4% (speculation on FY13/14 results) - Telecom: China Mobile 941.HK -2.2%, China Unicom 762.HK -3.7%, China Telecom 728.HK -2.5% (China's pilot VAT program)

>>> US After Hours

After Hours Summary: SKUL +14.8%, NTRI +14.2%, ELLI +11.3%, SQI -19.4%, BIRT -18.6%, INVN -15.3% following earnings/guidance

After Hours Gainers: Companies trading higher in after hours in reaction to earnings: SKUL +14.8%, NTRI +14.2%, ELLI +11.3%, TSYS +10%, IRIX +9.9%, MCHX +6.7%, AEM +5.6%, SQNM +5.2%, MCRS +4.1%, MODN +4%, ATEN +3.9%, ABTL +3.9%, HTGC +3.5%, EXEL +3.4%, QLGC +3.4%, WPRT +3.3%, FLT +2.7%, CTRL +2.6%, WYNN +2.5%, SSNC +2.3%, OUTR +2.1%, EGO +2%, MTZ +1.9%, AKAM +1.8%, LNT +1.7%, CHGG +1.5%, ITMN +1.4%, VRTX +1.2%, SEM +1.1%, WU +1%

Companies trading higher in after hours in reaction to news: MODN +4.0% (announced appointment of Mark Tisdel as Chief Financial Officer and Shail Khiyara as Chief Marketing Officer), NKA +1.5% (announced signing of contract with TransCanada Gas Storage Partnership), FLT +1.4% (signed a long term fuel card system processing contract with Chevron covering Asia-Pac and South Africa; announced contract to acquire Shell's SME fuel card customer portfolio in Germany, with plans to expand across Europe), VRTX +1.2% (announced that treatment with the combination of VX-661 and KALYDECO (ivacaftor) in a 28-day Phase 2 study showed statistically significant improvements in lung function in people with both the F508del mutation and G551D mutation who were already taking KALYDECO; co also reported earnings), 

After Hours Losers:

Companies trading lower in after hours in reaction to earnings: SQI -19.4%, BIRT -18.6%, INVN -15.3%, HTCH -13.8%, NGVC -11%, RBCN -10.8%, BCOR -9.9%, GERN -9.6%, KEYW -9.6%, AHS -8.6%, KOG -7.4%, SREV -7.2%, SWIR -7.2%, MTW -6.5%, CVD -6.3%, OPEN -5.4%, IMPV -4.4%, LNKD -4.4%, BBG -4%, CSOD -3.9%, FLR -3.4%, EHTH -3.3%, ONNN -2.5%, EXPE -2.5%, UPIP -2.3%, DVA -1.3%, ALJ -2.4%, LRE -1.1%, XPO -1.1%, TPX -1.1%

Companies trading lower in after hours in reaction to news: IMMU -13.0% (announced proposed public offering of common stock; size not disclosed), DRL -4.1% (Attiva Capital Partners disclosed 5.3% stake; co also said it is developing a revised capital plan to remain in compliance with regulators), TTPH -2.6% (filed for $125 mln mixed securities shelf),  offering), ATHN -2.4% (named Karl Stubelis acting Chief Financial Officer)

(Barron's) GMO'S Jeremy Grantham Remains Bullish on Stocks

GMO'S Jeremy Grantham Remains Bullish on Stocks

The famed investor says the S&P 500 can gain another 20% in coming years despite stretched valuations.

Editor's Note: Grantham is founder of GMO, a Boston-based money manager. This is a lengthy excerpt of his latest quarterly market commentary. A full version of this piece, with charts, is available on the GMO Website.

It is a sensible expectation that reasonable long-term value investors will endure pain in a bubble. It is almost a rule.

The pain will be psychological and will come from looking like an old fuddy-duddy…looking as if you have lost your way in the new golden era where some important things, which you have obviously missed, are different this time.

For professionals this psychological pain will also come from loss of client respect, which always hurts, and loss of peer group respect, which can be irritating.

In truth there is nothing much that we can do about this problem. Value investors must, as always, invest exclusively on long-term values and long-term risks. We must always build our portfolios from the best mix of these two characteristics. Therefore there is simply no alternative to standing our ground and taking it on the chin when crazy markets get even crazier. Our consolation will be in knowing that we will win in the end whereas if we start jumping around on other non-value considerations, who knows what might happen?

On the other hand, it is perhaps useful to be familiar with the various aspects of bubbles that may arrive to trouble us. It is in this spirit that this quarterly letter is written: to better prepare prudent investors for the probable future pain so that they can more easily process it and be less likely to do something foolish.

What is a bubble? Seventeen years ago in 1997, when GMO was already fighting what was to become the biggest equity bubble in U.S. history, we realized that we needed to define bubbles. By mid-1997 the price earnings ratio on the S&P 500 was drawing level to the peaks of 1929 and 1965 – around 21 times earnings – and we had the difficult task of trying to persuade institutional investors that times were pretty dangerous. We wanted to prove that most bubbles had ended badly. In 1997, the data we had seemed to show that all bubbles, major bubbles anyway, had ended very badly: all 28 major bubbles we identified had eventually retreated all the way back to the original trend that had existed prior to each bubble, a very tough standard indeed.

Having plenty of trained quants back then, it was no time before it was suggested that a two-standard-deviation (or 2-sigma) event might be a useful boundary definition for a bubble. In a normally distributed world, a 2-sigma event would occur every 44 years.

GMO has spent a lot of time during the last 17 years making a considerable review of minor bubbles as well as the 28 major ones that we covered originally in 1997. One thing was clear from the 330 examples we had studied: 2-sigma events in our real world have tended to occur not every 44 years, but about every 31 years. This was quite a bit closer to the 44 years of a random world than we originally would have guessed given that the world is fat-tailed but, frankly, it is convenient: once every 31 years, which would be a longish career in investing, feels like it perfectly fits the title of "bubble."

In my opinion, time has been kind to this definition in the intervening 17 years. A 2-sigma event now seems to me to be perfectly reasonable even if I have to admit it is completely arbitrary. Having a useful and practical definition of a bubble is important for I have come to believe that the forming and bursting of the great investment bubbles are by far the most important things that happen in investing. So, how do the great events of the past score on this 2-sigma definition? The six most important asset bubbles in modern times qualifies on the 2-sigma definition, although the 1965-72 peak, known in the trade then as the "Nifty-Fifty" event, did so by a modest margin.

This event fell short in providing the usual good examples of extreme investment craziness. Perhaps, though, the very definition of the Nifty Fifty as "one decision stocks" may have qualified it, with one extremely crazy theme substituting for many smaller ones, for "one decision stocks" were so named because you only had to make one decision: to buy.

These stocks were generally believed then to be so superior that once bought they would be held for life. (Most, like Coca-Cola and Merck, stood the test of time well enough, but unfortunately several then unchallengeable examples like Eastman Kodak and Polaroid went the way of all flesh, or all film.)

There is one very important event that influenced our lives, financial and otherwise: 2008. The U.S. housing market leaped past 2-sigma all the way to 3.5-sigma (a 1 in 5,000-year event!). The U.S. equity market, though, was overshadowed by the then recent record bubble of 2000, although it still made it to a 2-sigma event on some definitions. But what was unique about 2008 was the near universality of its asset class overpricing: every equity market, almost all real estate markets (Japan and Germany abstained), and, of course, a fully-fledged bubble in oil and many other commodities. The GMO Quarterly of April 2007 ("It's Everywhere, in Everything: The First Truly Global Bubble") started out: "From Indian antiquities to Chinese modern art; from land in Panama to Mayfair; from forestry, infrastructure, and the junkiest bonds to mundane blue chips; its bubble time."

But it took until last month for the penny to drop about how to make the point statistically. Using just the 40 countries for whom we have the best long-term equity data, we asked how many of these markets have been over one standard deviation at any given time together. In 2008 a higher percentage of the 40 equity markets were over that hurdle (a 1-sigma is the kind of event that occurs about once every six years in a random world) than ever before in our data, which starts in 1925. Interestingly, 1929 came the closest.

I must say I had not at all expected that. I have been carrying the quite false impression for almost 50 years that 1929 was overwhelmingly a U.S. market event, although I knew the crash was more universal. However, 2008 in contrast is unique in other ways too – in 1929, the housing market was more or less normal and the commodity markets were curiously very depressed.

So 2008, particularly if you can imagine adding real estate and commodities, was indeed a true global asset bubble, being the most extreme collective outlier in not just 30 years, but in at least the 88 years of our data and probably forever, given the much lower correlations of earlier times.

Thus, all the earlier major bubbles passed our 2-sigma test with flying colors. So now, to get to the nub, what about today? Well, statistically, We are far off the pace still on both of the two most reliable indicators of value: Tobin's Q (price to replacement cost) and Shiller P/E (current price to the last 10 years of inflation-adjusted earnings). Both were only about a 1.4-sigma event at the end of March. (This is admittedly because the hurdle has been increased by the recent remarkable Greenspan bubbles of 2000 and a generally overpriced last 16 years.)

To get to 2-sigma in our current congenitally overstimulated world would take amove in the S&P 500 to 2,250. And you can guess the next question we should look at: how likely is such a level this time? And this in turn brings me once again to take a look at the driving force behind the recent clutch of bubbles: the Greenspan Put, perhaps better described these days as the "Greenspan-Bernanke-Yellen Put," because they have all three rowed the same boat so happily and enthusiastically for so many years.

Out there in the wilds of the internet along with our free quarterly letter, which always feels like a long painful delivery, there is an equally free letter from John Hussman, who turns out to have the same work ethic as Alexey Stakhanov, that hero of the Soviet Union known for his massive and routine production over quota. Hussman, can you believe, produces a long and well-researched quarterly letter each week! Deplorable. Surely (he says enviously), he must be a workaholic and obviously unlike some of us less industrious types can have no life at all. But I will say this: he grinds some good data. He therefore makes a good representative of the analytical group, all value diehards who believe the market's demise is imminent. And the data is comprehensive enough that I admit it worries me. Clearly he and the others may be right.

Yellen's reprehensible choice of current price as a multiple of next year's estimated earnings. (Either she's painfully ill-informed or, most implausibly, not too smart, in which case sooner or later we're scr*w*d, or she knows this measure is a third-rate prediction of true value and is cynically using it to tout the market, in which case we're doubly scr*w*d! But at least that latter reason would be an ideal proof of her buying into her predecessors' Put, in case we had any doubt.)

But back to value and Hussman. Not surprisingly, GMO very much agrees with the spirit of this data, but our preferred measure for our 7-Year Forecast has the market slightly less overvalued at 65%. (Although, interestingly, at 2,250 – our 2-sigma target – it would be about 100% overpriced.) Our estimate allows for a very modest improvement in trend line profitability and an even more modest allowance for a slightly higher P/E as a response to probable lower equilibrium interest rates. Still our estimate of overpricing is pretty close to his.

Hussman's work suggests that whenever this large collection of troublesome predictions line up like they have recently there has been a very serious and fairly immediate market decline. While I have no quarrel with the eventual outcome and recognize that possibly the bear market's time may have come, particularly in light of recent market declines (April 13, 2014), I still think it's less likely than my suggestion of a substantial and quite lengthy last hurrah.

The January Rule Unlike my main thesis this quarter, I do have some support for the bears in the so-called January Rule: that the move in January predicts whether the balance of the year will be strong or weak.

The logic for the January Rule has always been that individuals have an unusual flow of investable funds at the end of the year from tax loss selling and from Christmas bonuses, and also at the end of the year ask themselves what lies ahead and act on that in early January and apparently get it moderately more right than wrong. In any case, the Rule seems to work. By a curious set of events, it turned out that our very first institutional account in late 1978 – a midwestern pension fund – was the only account we ever had that used this approach. It had three components: the Presidential Cycle, the January Rule, and a measure of monetary stimulus. It worked okay for two years, but just as soon as a new pension officer appeared, he fired us for having an approach that to him looked simple-minded and because we were busy doing traditional value stock picking by then, that that was the end of it. I offer this history to make the point that both the Presidential Cycle and the January Rule had excellent records then – 35 years ago – in simply predicting the outcome of each individual year. So when we review the 35 years that followed I find it more of a real-time experiment than data mining. What we found 35 years ago was that the first 5 trading days of each year had a good record of predicting a similar trend for the balance of the year. The same applied to the performance for the whole month of January.

Although this rule was old even then, as was the Presidential Cycle, and could be regularly found updated in the annual "Stock Traders' Almanac," what I found that was slightly new was that when the 5 days contradicted the January results, the following 11 months were close to a wash. Our interest, therefore, was in those cases in which the two pieces of data confirmed each other: what I thought of as "up ups" and "down downs." Since 1932 there have been 22 "up up" years. The average gain from February to December those years was 11.6%. Most remarkably, since my birth in 1938, only 1 of the 22 occurrences was below average and that was 1987, a year that spent the first months going up 35%, one of the strongest 9 months ever, before hitting the technical collapse caused, we believe, by the over-enthusiastic use of portfolio insurance.

Almost as remarkable have been the results of the 14 "down downs" since 1932, for which the average balance of the year is a dismal -6.6% with only 1982 showing a pretty big upside move. Remember, too, that even that year went down steadily through August until it hit seven times earnings and staged a late-year rally. It should be mentioned here that 2014 is a year in which both the first five days and the month of January were down – i.e., a "down down" year. It is also, until October 1, the weakest year of the Presidential Cycle, "a year two."

(Although the Greenspan gang has had a hard time not stimulating every year, so that 1998 and 2006 were two of the few year twos that had respectable performance as the Fed and the markets got carried away.) A very interesting question is why these two rules keep on working. Well, for one thing, to arbitrage the difference between a -6% year ("down down") and a +10% year ("up up") would take a lot of money. But more to the point, investors are very reluctant to take these two factors seriously. In fact, the factors are not respectable at all! They felt hokey and insubstantial 35 years ago and another very good 35 years of performance has not changed that. Managers seem embarrassed to talk about these factors and clients (based on our sample) are reluctant to consider them. And this of course is the point: they carry the career risk for professionals as being seen to be trivial, data mined, and just too simple to be true. Individuals, in contrast, probably find these outperformance tendencies to be too mild for their taste. The net effect is that no one (really, including GMO) acts on them and this is precisely why they have continued to work.

In the interest of full disclosure, I must confess that even as I studied these rules for decades I hardly used them at all, even personally, for reasons similar to those described. Today, older and wealthier and not exposed to career risk with my own money, I tilt a minimal amount away from "down down" years and toward year 3. Fortunately, I don't have to worry about anyone else (even GMO) following these two apparently useful rules.

With the repeated caveat that prudent investors should invest exclusively or nearly exclusively on a multi-year value forecast, my guesses are: 1) That this year should continue to be difficult with the February 1 to October 1 period being just as likely to be down as up, perhaps a little more so.

2) But after October 1, the market is likely to be strong, especially through April and by then or in the following 18 months up to the next election (or, horrible possibility, even longer) will have rallied past 2,250, perhaps by a decent margin.

3) And then around the election or soon after, the market bubble will burst, as bubbles always do, and will revert to its trend value, around half of its peak or worse, depending on what new ammunition the Fed can dig up.

Conclusion and Summary The bull market may come to an end any time, indeed as I write it may already have happened. It could be derailed by disappointing global growth, profits sagging as deficits are cut, a Russian miscalculation, or, perhaps most dangerous and likely, an extreme Chinese slowdown.

But I believe it probably (i.e., over 50%) will not end for at least a year or two and probably not before it reaches a level in excess of 2,250 on the S&P 500. Prudent long-term value investors will of course treat all of the above as attempted entertainment (although I believe all statistically accurate) and be prepared once again to prove their discipline and man-hoods (people-hoods) by taking it on the chin.

I am not saying that this time is different (attention Edward Chancellor). I am sure it will end badly. But given this regime of the Federal Reserve and given the levels of excess at other market peaks, I think it would be different to end this bull market just yet.

WSJ : Pfizer Enters Takeover Discussions With AstraZeneca

Pfizer Enters Takeover Discussions With AstraZeneca, Sources Say

Talks Resume After Pfizer Sweetens Terms of Earlier Takeover Offer for British Rival

Pfizer Inc. PFE -0.42% and AstraZeneca AZN.LN +0.27% PLC have resumed talks about a trans-Atlantic merger of the two drug giants, after Pfizer sweetened the terms of an earlier takeover offer for its British rival, according to people familiar with the matter.

The terms of the informal offer from New York-based Pfizer couldn't be learned. Its earlier approach, which was rejected, valued AstraZeneca at nearly $100 billion.

The renewed discussions suggest that the two sides might be getting closer to striking a friendly deal, though there is no guarantee they will go anywhere.

Pfizer made an offer to buy AstraZeneca in January that valued the British company at £46.61 a share. After the approach was disclosed this week, AstraZeneca said it "significantly undervalued" the company.

A box of Arthrotec 50 tablets, produced by Pfizer, and a box of EMLA cream, produced by AstraZeneca, are seen in this arranged photograph taken in London in April. Bloomberg A merger would create the world's biggest pharmaceutical company, selling drugs for most major conditions, including cancer, diabetes and heart disease. It would be one of the industry's biggest deals since Pfizer bought Warner-Lambert for $90 billion in 2000.

It could also help the companies deal with the billions of dollars in sales they are losing as blockbusters like cholesterol fighter Lipitor face competition from generic rivals. Each company had a sales drop of 6% last year, Pfizer's to $51.6 billion and AstraZeneca's to $25.7 billion.

Pfizer Chief Executive Ian Read has said the primary driver behind the proposed deal is a desire to build the strongest lineup of products across each of the company's businesses, including drugs that have lost patent protection but sell well in fast-growing emerging markets.

It would also link Pfizer's targeted cancer therapies with AstraZeneca's drug candidates that aim to use the body's immune system to fight the disease. Researchers believe different kinds of drugs need to be combined to improve cancer treatment.

A deal might also strengthen each of Pfizer's three business units enough that the company would divide into separate companies, an option executives have said they are exploring.

Pfizer executives have indicated they would use some of the company's cash reserves earned and kept overseas to pay for a deal. Pfizer had $49 billion in cash and equivalents outside the U.S. at the end of last year.

Pfizer executives have also said they would domicile the combined company in the U.K. to lower its tax rate. And they have also said they would expect to cut costs.

Pfizer first approached London-based AstraZeneca last November, and the companies met in New York in January, AstraZeneca said Monday. At that meeting, Pfizer proposed a deal consisting of 70% Pfizer stock and 30% cash, according to AstraZeneca.

AstraZeneca said it rejected the offer on Jan. 12, because its board was concerned about the large proportion of Pfizer stock and the challenges of structuring the deal so a combined company would pay U.K. tax rates.

Pfizer approached AstraZeneca again on April 26 about doing a deal, but AstraZeneca said it wasn't interested "absent a specific and attractive proposal," the British company said.

Under U.K. takeover rules, Pfizer has until May 26 to make a firm proposal or disclose that it is no longer interested in an acquisition.

>>> US Close Dow-0,13% S&P-0,01% Nasdaq+0,31%

Closing Market Summary: S&P 500 Ends Flat While Small Caps Lag

The stock market ended on a cautious note after enduring a sloppy session that lacked concerted sector leadership. The S&P 500 settled right below its flat line, while the Russell 2000 lost 0.5% after displaying intraday volatility.

Equities began the first session of May near their flat lines amid the lack of leadership from overseas as most global markets were closed for Labor Day. Despite the quiet open, small caps were active from the get-go as the Russell 2000 retreated as much as 1.1% during the first hour of action. The index halted its slide at the 200-day moving average (1113.73), which has been acting as an area of support since mid-April.

The subsequent reversal took place as fast as the early slide, placing the Russell 2000 ahead of the remaining indices. The late-morning strength began fading into the afternoon, which sent the small-cap index back towards its morning low.

Meanwhile, the S&P 500 spent the bulk of the afternoon within four points of its flat line as individual sectors traded in mixed fashion. Most notably, consumer discretionary (+0.4%) and utilities (+0.3%) outperformed throughout the session, with the utilities sector extending its 2014 advance to 14.0%.

For its part, the discretionary sector was boosted by media names amid reports indicating AT&T (T 35.58, -0.12) approached DirecTV (DTV 80.76, +3.16) about a potential $40 billion acquisition. Momentum names also served as support to the sector as Amazon.com (AMZN 307.89, +3.76), Netflix (NFLX 336.52, +14.48), and Priceline.com (PCLN 1180.60, +22.85) jumped between 1.2% and 4.5%.

Staying on the momentum theme, high-growth names also played a part in the outperformance of the Nasdaq Composite (+0.3%). High-beta listings held up well after Yelp (YELP 64.02, +5.70) reported better than expected earnings and revenue. Another measure of support came from the shares of Facebook (FB 61.15, +1.37), which rallied 2.3% after being added to the U.S. Focus List at Credit Suisse.

Elsewhere, biotechnology climbed, which also contributed to the Nasdaq's relative strength. The iShares Nasdaq Biotechnology ETF (IBB 232.50, +2.25) gained 1.0%, while the broader health care sector ended flat. The third-largest group saw an intraday spike amid reports Pfizer (PFE 31.15, -0.13) may up its bid for AstraZeneca (AZN 81.09, +2.04).

Also of note, the leading sector from April, energy (-0.4%), finished near the bottom of the leaderboard as top component (and Dow member) ExxonMobil (XOM 101.41, -1.00) weighed. The stock lost 1.0% after beating earnings estimates on below-consensus revenue.

On the fixed income side, Treasuries rallied throughout the session, which was a bit perplexing. The benchmark 10-yr yield fell to 2.61%, settling not far above its lowest close of the year (2.58%).

That move was supported in part by the weaker than expected initial claims report, but the interesting thing was that it held up in the wake of the stronger than expected ISM Index and in front of the April employment report on Friday. The continued buying interest in the benchmark note, which has been seen all year, isn't something one would expect to see if there was a strong belief that the economy is getting ready to hit escape velocity.

Participation was a bit below average as 682 million shares changed hands at the NYSE floor.

Looking back at today's data:
The initial claims level increased to 344,000 for the week ending April 26 from an upwardly revised 330,000 (from 329,000) for the week ending April 19. That was the highest initial claims reading since February, while the consensus expected the claims level to fall to 315,000. There were no special factors cited for the increase, but in all likelihood, the recent volatility has resulted from seasonal adjustment issues surrounding the Easter holiday.
Personal income increased 0.5% in March after increasing an upwardly revised 0.4% (from 0.3%) in February. The consensus expected income to increase 0.4%.
Personal spending also topped expectations, increasing 0.9% in March after increasing an upwardly revised 0.5% (from 0.3%) in February.
Core PCE prices increased 1.2% y/y and remain well below the Fed's 2.0% target.
The April Challenger Job Cuts report indicated a 6.0% year-over-year increase to follow the previous decline of 30.2%.
The ISM Manufacturing Index increased to 54.9 in April from 53.7 in March. The consensus expected the ISM Manufacturing Index to increase to 54.5. The gain in the ISM Index was in-line with the improvements reported in the regional Federal Reserve manufacturing surveys released throughout April.
Construction spending increased 0.2% in March after falling a downwardly revised 0.2% (from +0.1%) in February. The consensus expected construction spending to increase 0.4%. The extreme winter weather in January and February did not lead to a release in pent up demand, suggesting the weather effects may have been overstated.
Tomorrow, the Nonfarm Payrolls report for April (consensus 210,000) will be released at 8:30 ET, while March Factory Orders (consensus 1.6%) will be announced at 10:00 ET.

S&P 500 +1.9% YTD
Dow Jones Industrial Average -0.1% YTD
Nasdaq Composite -1.2% YTD
Russell 2000 -3.0% YTD

WSJ : AT&T's Direct Route into Cable Fray

AT&T's Direct Route into Cable Fray
It has been a while since U.S. telecom companies first got up in pay TV's business. But recent stirrings on the merger front show the industries are drawing ever closer.
In the latest example, AT&T reached out to DirecTV about a possible acquisition of the satellite-TV operator, The Wall Street Journal reported. Together, in video the two companies would rival the scale of a combined Comcast and Time Warner Cable, should a proposed deal between those two receive regulatory approval.
Indeed, Comcast's merger effort may have spurred AT&T to act, seemingly abandoning ambitions of expanding into Europe. AT&T's courting of DirecTV also comes against a backdrop of mounting competition—and possible consolidation—in the wireless industry along with the dual promises of wireless broadband and cable-Wi-Fi-enabled phone networks.
Tying up with AT&T could make sense for DirecTV, whose subscriber-growth rate has fallen year over year since 2010. As a satellite provider, DirecTV lacks its own broadband offering, which puts it at a disadvantage to cable peers.
AT&T's fiber broadband could fill that gap. For AT&T, buying DirecTV would give it access to the satellite company's free-cash flow. That could be valuable, as roughly 85% of AT&T's free cash flow is expected to go toward its dividend in 2014. And doubling down on video would make AT&T less exposed to wireless at a time when aggressive promotions by T-Mobile US have been shaking up the industry.
But buying DirecTV, which has an enterprise value of $59.5 billion, would hardly solve all of AT&T's problems. AT&T would be tying itself to a business in structural, if gradual, decline. Doing a deal also would mean passing up the opportunity to buy the satellite-TV company that also comes with a sizable swath of wireless spectrum: Dish Network.
Getting Dish to the bargaining table may, in fact, be AT&T's primary goal in talking to DirecTV. Indeed, Dish shares rose more than those of DirecTV Thursday.
Reports in March that Dish had approached DirecTV about a deal were viewed by some investors as Dish trying to flush out a buyer such as AT&T or Verizon Communications. The talks with DirecTV could be AT&T's way of returning the favor, essentially trying to spook Dish into lowering its price ambitions by threatening to buy its satellite rival.
Price would be a major hurdle to an AT&T bid for Dish. Charlie Ergen, the latter's chairman, controls the company and is likely to demand a significant premium. AT&T's latest move probably won't change that.
Still, with Dish, AT&T would get its hands on airwaves that it might otherwise have to buy at auction later on. It also would be keeping Dish's spectrum out of the hands of Verizon, which is focused on paying down debt from its acquisition of the rest of Verizon Wireless.
Granted, a deal with DirecTV might be simpler from a regulatory standpoint than with Dish due to the spectrum component. But the Federal Communications Commission will likely raise spectrum-ownership limits in a vote on May 15, easing the path for AT&T.
And, while not a slam dunk, an AT&T satellite deal would likely face less regulatory scrutiny than a possible Sprint bid for T-Mobile, according to Guggenheim Partners. Comcast's bid for Time Warner Cable also could pave the way for AT&T because the telecom company would look smaller from a video-subscriber perspective by comparison.
AT&T may not end up tying the knot with either satellite player. But the telecom and pay-TV industries are likely to get more entangled.
Write to Miriam Gottfried at Miriam.Gottfried@wsj.com

Fwd: T(Makor) Long Danone / Short Nestle, Unilever



Top Trading Ideas: long Danone / short Nestle, (Unilever plc)

 

We re-initiate the trade long Danone / short Nestle and and a smaller position in long Danone / short Unilever Plc (note we recommend to short the UK listing – not the Dutch listing which is cheaper – in fact we do have a recommended share class arb long UNA NA / short ULVR LN).

 

The trade is justified by relative value (vs. Nestle), mean reversion, and a recent price dislocation.

 

FULL REPORT ATTACHED